+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating two experimental medicines, freneslerbart and mevonlerbart, alone or combined as REGN-2Cat, in people with allergic conjunctivitis caused by cat hair or dander. The study aims to understand side effects and whether these medicines can reduce eye allergy symptoms compared to a placebo. It is a phase 3, randomized, double-masked, placebo-controlled trial sponsored by Regeneron Pharmaceuticals. Participants may receive freneslerbart, mevonlerbart, REGN-2Cat the combination, or placebo according to the study protocol. The study investigates different doses and combinations to monitor how much medicine is in the blood over time, the bodys immune response to the drugs, and the duration of the drug effects. The intervention is given during the treatment period, with assessments following conjunctival allergen challenges. Participants will have eye allergy symptoms assessed, including ocular itch and redness scores after allergen exposure. Researchers will also measure immune responses, drug levels in the blood, and monitor for side effects up to about 113 days. The study involves regular visits for testing, including skin prick tests and conjunctival allergen challenges, to evaluate treatment effects and safety throughout the trial duration.

Age: 8Years +All GendersPhase 3
1 location
E

Actively Recruiting

Researchers are studying the safety and effectiveness of VSJ-110, an eye drop solution, compared to a placebo in treating dry eye. This phase 2 clinical trial aims to provide important information about how well VSJ-110 works and how safe it is for people with dry eye over an eight-week period. The study is randomized and double-masked, meaning neither participants nor researchers know who receives the treatment or placebo during the trial. Participants will be randomly assigned to receive either the VSJ-110 ophthalmic solution or a placebo solution. Both treatments are delivered as eye drops, and the study lasts for eight weeks. The trial is designed to closely monitor the participants response to treatment and any side effects that may occur during this time. Throughout the study, participants will attend scheduled visits where various assessments will be performed. These include measuring corneal staining, which shows eye surface damage, and performing Schirmers Tear Test to evaluate tear production. Participants will also report their eye dryness using a visual scale. The research team will monitor safety and collect data to evaluate the outcomes over the full eight weeks of treatment.

Age: 18Years +All GendersPhase 2
5 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.

Age: 18Years +All GendersPhase 3
9 locations
A

Actively Recruiting

Researchers are studying the effects of over-the-counter lubricating eye drops on comfort, symptoms, and vision in adults with dry eye disease DED. This Phase 4 randomized study aims to compare the tolerability and visual outcomes of different preservative-free eye drops in people who have experienced dry eye symptoms for at least six months. The study focuses on evaluating how these products impact patient-reported symptoms and ocular surface health. Participants will be randomly assigned to receive one of several preservative-free lubricating eye drops, including Blink Triple Care and Systane variants, administered multiple times daily, such as four times daily QID or twice daily BID, depending on the specific product. The study treatment period lasts at least 14 days, during which participants will use the assigned eye drops according to the specified dosing schedule. Treatments are compared to assess comfort and symptom relief. During the study, participants will attend scheduled visits to assess dry eye symptoms using the Ocular Surface Disease Index OSDI over 14 days. They will be monitored for symptoms, tolerability, and visual function throughout the treatment period. Researchers will collect information on symptom relief and safety to understand the effects of the lubricating eye drops. Total participation and follow-up extend through the treatment period up to study completion.

Age: 18Years +All GendersPhase 4
1 location